| Dr Joseph Ahlstrom Chiara, MD | |
|
3806 East Bell Road, Suite 5800, Phoenix, AZ 85032-2160 | |
| (602) 688-6500 | |
| (602) 867-3144 |
| Full Name | Dr Joseph Ahlstrom Chiara |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 19 Years |
| Location | 3806 East Bell Road, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912113085 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 46992 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Honorhealth Deer Valley Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Valley Ear Nose And Throat Associates Pc | 3173427036 | 5 |
News Archive
This BMJ feature examines why India's dengue epidemic continues to grow worse each year, stating, "In the past decade, according to the National Vector Borne Disease Control Programme (NVBDCP), the number of cases has escalated steadily from 3,306 in 2001 to 47,209 in 2012," and "[d]eaths have risen from 53 in 2001 to 242 in 2012."
This Kaiser Health News table lists the top ten regions in the nation regarding growth in Medicare spending, comparing the total Medicare reimbursement per enrollee in 2000 and 2007 (Rau, 5/25).
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
UC San Diego Health System is among the nation's "Most Wired Advanced" hospitals, according to new findings released by Hospitals & Health Networks (H&HN), a publication of the American Hospital Association.
Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.
› Verified 1 days ago
| Entity Name | North Valley Ear Nose & Throat Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457493165 PECOS PAC ID: 3173427036 Enrollment ID: O20031121000562 |
News Archive
This BMJ feature examines why India's dengue epidemic continues to grow worse each year, stating, "In the past decade, according to the National Vector Borne Disease Control Programme (NVBDCP), the number of cases has escalated steadily from 3,306 in 2001 to 47,209 in 2012," and "[d]eaths have risen from 53 in 2001 to 242 in 2012."
This Kaiser Health News table lists the top ten regions in the nation regarding growth in Medicare spending, comparing the total Medicare reimbursement per enrollee in 2000 and 2007 (Rau, 5/25).
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
UC San Diego Health System is among the nation's "Most Wired Advanced" hospitals, according to new findings released by Hospitals & Health Networks (H&HN), a publication of the American Hospital Association.
Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Ahlstrom Chiara, MD 3805 East Bell Road, Suite 5800, Phoenix, AZ 85032-2162 Ph: (602) 688-6500 | Dr Joseph Ahlstrom Chiara, MD 3806 East Bell Road, Suite 5800, Phoenix, AZ 85032-2160 Ph: (602) 688-6500 |
News Archive
This BMJ feature examines why India's dengue epidemic continues to grow worse each year, stating, "In the past decade, according to the National Vector Borne Disease Control Programme (NVBDCP), the number of cases has escalated steadily from 3,306 in 2001 to 47,209 in 2012," and "[d]eaths have risen from 53 in 2001 to 242 in 2012."
This Kaiser Health News table lists the top ten regions in the nation regarding growth in Medicare spending, comparing the total Medicare reimbursement per enrollee in 2000 and 2007 (Rau, 5/25).
OncoGenex Pharmaceuticals Inc. today announced that it concluded a meeting with the U.S. Food and Drug Administration (FDA) on October 7, 2008, and that the FDA agreed that "durable pain palliation is an acceptable and desirable study endpoint" to support a product marketing approval for OGX-011 as a treatment for hormone refractory prostate cancer (HRPC).
UC San Diego Health System is among the nation's "Most Wired Advanced" hospitals, according to new findings released by Hospitals & Health Networks (H&HN), a publication of the American Hospital Association.
Emergent BioSolutions Inc. announced today it has entered into a definitive agreement to acquire Trubion Pharmaceuticals, Inc. for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. The acquisition will diversify Emergent's product development pipeline with the addition of Trubion's two clinical-stage product candidates focused on the targeted disease areas of oncology and autoimmunity.
› Verified 1 days ago
Dr. Shawn Michael Stevens, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 | |
Charles R Orozco, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 4250 E Camelback, Suite K-250, Phoenix, AZ 85018 Phone: 602-253-9026 Fax: 602-252-6391 | |
John David Macias, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1515 N 9th St, Suite B, Phoenix, AZ 85006 Phone: 602-257-4228 Fax: 602-252-6416 | |
Dr. Michael L Hinni, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 5779 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-301-8000 | |
Randy Oppenheimer, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 2601 E Roosevelt St, Department Of Surgery, Phoenix, AZ 85008 Phone: 602-344-5608 Fax: 602-344-1299 | |
Austin N Dehart, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1920 E Cambridge Ave Ste 201, Phoenix, AZ 85006 Phone: 602-933-3277 Fax: 602-933-4326 | |
Griffin Santarelli, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2910 N 3rd Ave # 330, Phoenix, AZ 85013 Phone: 602-406-8811 Fax: 602-406-8810 |